Physician profile
Sandra L Weidner
NPI 1629074943
$981.89
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $260 · 2021: $268 · 2022: $188.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $134.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $105.81 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $101.54 | 2021-2022 | |
| Pfizer INC. | $98.53 | 2019-2021 | |
| Tris Pharma INC | $89.43 | 2019-2021 | |
| Shire North American Group INC | $58.63 | 2019 | |
| Sanofi Pasteur INC. | $55.48 | 2019-2020 | |
| Kaleo, INC. | $38.67 | 2019-2022 | |
| Corium, LLC | $30.23 | 2022 | |
| Adlon Therapeutics L.P. | $29.33 | 2020 | |
| Sobi, INC | $25.46 | 2021 | |
| Genentech USA, INC. | $20.51 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.34 | 2022 | |
| Biofire Diagnostics, LLC | $16.13 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $15.89 | 2022 | |
| Mission Pharmacal Company | $14.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Weidner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.